Keck School of Medicine of USC
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1885-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.keck.usc.edu
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
PO Methadone Ortho Outpatient
- Conditions
- Arthroscopic Knee RepairArthroscopic Hip Repair
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Keck School of Medicine of USC
- Target Recruit Count
- 100
- Registration Number
- NCT06351215
- Locations
- 🇺🇸
USC Healthcare Consultation 3, Los Angeles, California, United States
Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants
- Conditions
- Respiratory Distress Syndrome, Newborn
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Keck School of Medicine of USC
- Target Recruit Count
- 50
- Registration Number
- NCT05961670
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
Evaluating Pressures During Non-invasive Ventilation Utilizing NIV Plus Software
- Conditions
- Apnea of NewbornRespiratory Distress Syndrome, Newborn
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Keck School of Medicine of USC
- Target Recruit Count
- 100
- Registration Number
- NCT05961683
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
News
Novel Compound SHP1705 Targets Circadian Clock to Combat Aggressive Glioblastoma
A new experimental compound SHP1705 specifically targets circadian clock proteins hijacked by glioblastoma stem cells, impairing their ability to survive and grow in preclinical studies.
USC Study Confirms Safety Profile of COVID-19 Treatments: Paxlovid and Other Antivirals Show Minimal Serious Side Effects
A comprehensive review by USC's Keck School of Medicine found that most FDA-approved COVID-19 treatments, particularly oral antivirals like Paxlovid, cause few serious side effects.